Karios Technologies, LLC

Karios Technologies LLC is a for-profit organization that develops innovative biomaterial technologies for surgical and medical applications. The company was registered in SAM.gov on July 16, 2020, and is structured as a corporate entity.

Through federal grants, Karios Technologies has focused on developing novel hydrogel-based products for surgical applications, particularly in preventing post-surgical adhesions and managing bleeding. The National Science Foundation awarded Karios a $274,954 SBIR Phase I grant to develop a ready-to-use, large volume delivery system for in situ forming biomaterials with applications as a tissue sealant, scar tissue reductant, and drug/cell delivery vehicle during surgical procedures. The National Institutes of Health awarded Karios a $350,000 grant under the Cardiovascular Diseases Research program to develop TissueShield, a sprayable hydrogel designed to prevent post-surgical cardiac adhesions. Additionally, Karios received a $4,073,888 grant from the NIH to optimize and evaluate the efficacy and safety of TissueShield in a large animal cardiac adhesions model. These grants demonstrate Karios' expertise in developing innovative biomaterials for surgical applications, with a focus on preventing adhesions, managing bleeding, and delivering drugs or cells.